While a few preliminary studies have pointed to a potential clinical benefit of TSPO PET in glioblastoma patients attributed to additional information as compared to established imaging modalities [13,14], the potential of TSPO imaging in preclinical studies is currently a thriving and promising field in order to better understand the glioma microenvironment [15]. The gene discussed is TSPO; the disease is central nervous system cancer.